Last quarter (Q3 2023), Xilio Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Xilio Therapeutics's net income was $-16.75M. See Xilio Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	-	-	-	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
Operating Expense	$ 84.17M	$ 89.15M	$ -75.04M	$ 54.56M	$ 19.03M
Operating Income	$ -84.17M	$ -89.15M	$ -75.04M	$ -54.56M	$ -19.03M
Net Non Operating Interest Income Expense	$ 12.00K	$ -12.00K	$ 16.00K	-	-
Other Income Expense	$ -2.96M	$ -927.00K	$ 756.00K	$ -656.00K	$ 1.72M
Pretax Income	$ -81.22M	$ -88.22M	$ -75.80M	$ -55.22M	$ -17.31M
Tax Provision	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-
Net Income Common Stockholders	$ -81.22M	$ -88.22M	$ -75.80M	$ -55.22M	$ -17.31M
Basic EPS	$ -2.96	$ -3.22	$ -13.52	$ -2.07	$ -0.65
Diluted EPS	$ -2.96	$ -3.22	$ -13.52	$ -2.07	$ -0.65
Basic Average Shares	$ 109.82M	$ 27.39M	$ 5.61M	$ 26.67M	$ 26.67M
Diluted Average Shares	$ 109.82M	$ 27.39M	$ 5.61M	$ 26.67M	$ 26.67M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	$ 84.17M	$ 89.15M	$ -75.04M	$ 54.56M	$ 19.03M
Net Income From Continuing And Discontinued Operation	$ -81.22M	$ -88.22M	$ -75.80M	$ -55.22M	$ -17.31M
Normalized Income	$ -15.29M	-	-	$ -55.22M	$ -17.31M
Interest Expense	-	-	-	-	-
EBIT	$ -81.23M	$ -88.21M	$ -75.82M	$ -54.56M	$ -19.03M
EBITDA	$ -79.29M	$ -86.36M	$ -74.32M	$ -53.50M	$ -18.79M

Currency in USD

Xilio Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing